Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

By R. Schlenk, K. Döhner, J. Krauter, S. Fröhling, A. Corbacioglu, L. Bullinger, Marianne Habdank, D. Späth, M. Morgan, Axel Benner and 4 more. New England Journal of Medicine, 2008

1,664 citations recorded by the source corpus.

Subfields: Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/f012ea5c5467f34b8bfa9c6c5207ac80df16e1f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

Citations in the corpus

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia (2011, background): “Mutations in NPM1 , FLT3 and NRAS have also been reported in this diseas”
Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis (2015, background): “Cytogenetically normal patients are an important cohort for survival analysis, as they comprise ~45% of all AML cases and present an intermediate risk group whose survival is not dominated by karyotypic factors (Schlenk et al., 2008).”
Stem cell gene expression programs influence clinical outcome in human leukemia (2011, background): “Cytogenetically normal AML represents ∼45% of all AML cases and identifies a subject population of intermediate ris”
The role of mutations in epigenetic regulators in myeloid malignancies (2012, background): “In addition, recent candidate-gene and next-generation sequencing studies have identified novel recurrent somatic mutations in patients with myeloid diseases, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) (1, 2).”
MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L (2011, positive): “Conventional chromosome banding and fluorescence in situ hybridization (FISH) were performed as previously described (Schlenk et al., 2008).”
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (2009, background): “However, higher CD47 expression was strongly correlated with the presence of FLT3-ITD (p < 0.001), which is observed in nearly one-third of AML with normal karyotypes and is associated with worse overall survival (Mrozek et al., 2007; Schlenk et al., 2008).”